Clinical Study of the BioVentrix Revivent TC™ System for Treatment of Left Ventricular Aneurysms (ALIVE)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 126
- 试验地点
- 30
- 主要终点
- The rate of all cause of death, mechanical support, and operation (or re-operation) for HF, bleeding or tamponade from 1 through 12 months post procedure compared to untreated patients who remain on Guideline Directed Medical Therapy (GDMT).
研究概览
简要总结
A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System, with 2:1 study vs. active concurrent control group allocation ratio. This study will include 126 patients of which 84 patients will be treated with the investigational device and 42 patients will be included in an active control group.
详细描述
The Revivent TC System is indicated for patients referred for surgical treatment of left ventricular scar that is contiguous, and includes both anterior and septal components. Primary and Secondary Effectiveness Endpoints will compare data from the patients treated with the Revivent TC System to a control pool of patients who comply with all aspects of the protocol except scar location and are not treated with the investigational devices but remain on Guideline Directed Medical Therapy (GDMT). The primary safety and effectiveness endpoints will be evaluated at 12 months post procedure. The study will be conducted at a maximum of 20 clinical centers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years old or older
- •LV Aneurysm or Scar Presence: Defined by presence of a contiguous acontractile (akinetic and/or dyskinetic) scar;
- •LV Aneurysm/Scar Location: Defined as a scar involving septum and/or anterior, apical or anterolateral regions of the left ventricle as evidenced by cardiac imaging and referred for surgical management;
- •Viability of myocardium in regions remote from area of intended scar exclusion as evidenced by cardiac imaging;
- •Left Ventricular Ejection Fraction < 45%;
- •Left ventricular end-systolic volume index ≥50 mL/m2;
- •Suffering from heart failure symptoms as defined by NYHA Classification > 2 not responsive to medical therapy;
- •Patient completed 6 Minute Walk Test and MLHF Quality of Life Questionnaire (can be performed at baseline visit);
- •Patient is on adequate Guideline Directed Medical Therapy (GDMT);
- •Subject or a legally authorized representative must provide written informed consent;
- •Agree to required follow-up visits; and
- •Female subject of childbearing potential does not plan pregnancy for at least one year following the index procedure. For a female of childbearing potential, a pregnancy test must be performed with negative results known within seven days prior to index procedure Candidates for the study group must meet ALL of the inclusion criteria.
- •Candidates allocated to active concurrent control pool of patients must meet all inclusion criteria (including LV Aneurysm/Scar Presence), WITH THE EXCEPTION OF ONE OF THE FOLLOWING:
- •They have undergone previous pericardiotomy, left thoracotomy, or open heart surgery, or
- •The LV Aneurysm/Scar location does not permit treatment with the study device, or
- •The patient elects to be enrolled in the control group
排除标准
- •Candidates will be excluded from the study and active concurrent control group if ANY of the following conditions are present:
- •Cardiac Resynchronization Therapy (CRT) or ICD pacing lead placement ≤ 60 days prior to enrollment;
- •Valvular heart disease, which in the opinion of the investigator, will require surgery;
- •Functional Mitral Regurgitation greater than moderate (i.e. EROA>20mm sq.) and degenerative MR (including MR due to papillary muscle rupture);
- •Need for coronary revascularization, in the opinion of the site investigator;
- •Peak Systolic Pulmonary Arterial Pressure > 60 mm Hg via echo or right heart catheterization and/or evidence of cor pulmonale;
- •Myocardial Infarction within 90 days prior to enrollment;
- •Within the last six months, a prior CVA or TIA, or any intracranial hemorrhage, or any permanent neurologic deficit, or any known intracranial pathology;
- •Co-morbid disease process with life expectancy of less than one year or active malignancy not in remission;
- •Any solid organ transplant or is on waiting list for any solid organ transplant other than cardiac;
- •Chronic renal failure with a serum creatinine >2.5 mg/dL and/or GFR<30ml/min;
- •Subject is currently participating in another clinical trial that has not yet completed its primary endpoint;
- •Presence of significant ventricular arrhythmias
- •The following exclusion criteria apply only to the treatment group and do not apply to the concurrent control cohort:
- •Contraindication or inability to adhere to systemic anticoagulation;
- •Known hypersensitivity or contraindication to device materials;
- •Previous pericardiotomy or left thoracotomy;
- •Pathology/previous surgery/radiation therapy of the right neck that would interfere with placement of a 14F delivery catheter;
- •Prior open heart surgery or significant pericarditis;
- •Calcified ventricular wall in the area of intended anchor implants as verified by cardiac imaging;
- •Thrombus or intra-ventricular mass in the left atrium or ventricle as verified by cardiac imaging that has not been adequately treated with anticoagulant.
- •Functioning pacemaker leads in antero-apical RV, which, in the opinion of the investigator, would interfere with anchor placement;
研究组 & 干预措施
Treatment
Treatment with the Revivent TC System
干预措施: Revivent TC (Device)
Control Pool
Treatment with Guideline Directed Medical Therapy for Heart Failure Symptoms Only
结局指标
主要结局
The rate of all cause of death, mechanical support, and operation (or re-operation) for HF, bleeding or tamponade from 1 through 12 months post procedure compared to untreated patients who remain on Guideline Directed Medical Therapy (GDMT).
时间窗: 1 Year
A composite of all cause of death, placement of a mechanical support device and operation (or re-operation) for HF, bleeding or tamponade from 1 through 12 months (day 31 through 365) post procedure. Data from patients treated with the Revivent TC System will be compared to data from a control pool of patients who comply with all aspects of the protocol except scar (aneurysm) location and are not treated with the investigational devices remain on Guideline Directed Medical Therapy (GDMT). Patients in the GDMT group will be evaluated from day 31 through 365 after the date of enrollment into the study.
Incidence of all cause death, mechanical support, emergent cardiac surgery, prolonged mechanical ventilation, renal failure and clinically important stroke compared to data from the STS database for surgical LV aneurysm repair.
时间窗: 1 Month
Composite primary safety endpoint of all cause death, placement of a mechanical support device intra or post-op (IABP, VAD, ECMO or catheter based), emergent cardiac surgery including reoperation for bleeding or tamponade, prolonged mechanical ventilation, renal failure and clinically important stroke (Rankin Score of 4 or higher) through 30-days post procedure. Data from the patients treated with the Revivent TC System will be compared to surgical outcomes data from the Society for Thoracic Surgery database for surgical LV aneurysm repair.
次要结局
- The rate of re-hospitalization and improvement of HF Symptoms in patients treated with the test device compared to patients who are maintained on Guideline Directed Medical Therapy.(1 year)